Inhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cells

Basit Öğe Kaydı
dc.authoridGECGEL, Karaca Kaan/0000-0001-5231-857X
dc.contributor.authorGecgel, Karaca Kaan
dc.contributor.authorMuduroglu, Mustafa
dc.contributor.authorErdogan, Suat
dc.date.accessioned2024-06-12T10:54:26Z
dc.date.available2024-06-12T10:54:26Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: Androgen deprivation therapy (ADT) is one of the main strategies to treat prostate cancer (PCa) at various stages of its development. Androgen receptor (AR) antagonists such as enzalutamide are mainstay treatments for castration-sensitive prostate cancer. Though, a majority of patients initially respond to ADT, most will eventually progress to castrate-resistant, due to the development of different mutations on the AR. PCa cells express high telomerase activity, and there is a correlation between the total activity of telomerase and the Gleason score. Therefore, we hypothesized that the combination of enzalutamide plus a telomerase inhibitor could be more effective than enzalutamide alone in decreasing cell survival. Methods: In this study MTT test, RT-qPCR and image-based cytometry were used to investigate cell viability, apoptosis and cell cycle progression of androgen-responsive human prostate cancer LNCaP cells. The cells were treated with 5 mu M enzalutamide and 40 mu M telomerase inhibitor BIBR 1532, or with their combinations for 72 hrs. Results: Enzalutamide and BIBR 1532 alone inhibited cell proliferation in a dose-dependent manner. The combinations of the two agents could synergistically induce apoptotic and necrotic cell death. Either inhibition of telomerase by BIBR 1532 or AR blockages by enzalutamide decreased prostate-specific antigen (PSA) and the catalytic component of telomerase, hTERT, expression. Conclusion: These results suggest that telomerase inhibition therapy may contribute to the efficacy of enzalutamide in the androgen-sensitive PCa model.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey [Bideb 2209/A-2015]en_US
dc.description.sponsorshipThis study was supported by a grant from the Scientific and Technological Research Council of Turkey (project no: Bideb, 2209/A-2015 to KKG and MM). We would like to thank Kader Turkekul and Riza Serttas for their technical assistance.en_US
dc.identifier.endpage1576en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue6en_US
dc.identifier.pmid29332354en_US
dc.identifier.startpage1570en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19058
dc.identifier.volume22en_US
dc.identifier.wosWOS:000417154000030en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBIBR 1532en_US
dc.subjectEnzalutamideen_US
dc.subjectLncap Cellsen_US
dc.subjectProstate Canceren_US
dc.subjectTelomeraseen_US
dc.subjectLeukemia-Cellsen_US
dc.subjectReceptoren_US
dc.subjectBibr1532en_US
dc.subjectProliferationen_US
dc.subjectCombinationen_US
dc.subjectExpressionen_US
dc.subjectHterten_US
dc.titleInhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cellsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu